PharmacoEconomics & Outcomes News 665 - 27 Oct 2012

■ Pegademase [Adagen] co-pay fees will be coveredby Sigma-Tau in an expansion of its assistanceprogramme for patients with adenosine deaminase-severe combined immunodeficiency disease.Pegademase injection is the only commercially-available enzyme replacement therapy for thesepatients. In addition to an existing Compassionate UseProgram, Sigma-Tau will now also cover 100% of anyout-of-pocket costs incurred by patients whenpurchasing pegademase. Marcia Boyle, president ofthe Immune Deficiency Foundation, commented that"Sigma-Tau are to be commended, not only forinvesting in a vital therapy for an extremely rarepopulation, but also for recognizing that some patientsand families will need co-pay assistance for thistherapy".Sigma-Tau Pharmaceuticals Inc. Sigma-Tau Pharmaceuticals Inc. Offers NewCo-Pay Assistance Program for Adagen(R) Patients. Media Release : 9 Oct2012. Available from: URL: http://www.sigmatau.com 809142129

1

PharmacoEconomics & Outcomes News 27 Oct 2012 No. 6651173-5503/10/0665-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved